New hope for brain tumor patients: drug trial targets recurrent meningioma
NCT ID NCT07428616
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a drug called zanzalintinib in 100 people with meningioma that has returned or worsened after standard treatments like surgery or radiation. The goal is to see if the drug can shrink tumors or slow the disease. Participants take the drug by mouth, and researchers will monitor tumor response and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanzalintinib (a drug taken by mouth that targets tumor growth)
What this could lead to
If it works, this could offer a new treatment option for people with meningioma that has come back or worsened after standard therapies.
What could go wrong
This is a mid-stage trial with only 100 participants, so results may not apply to everyone. The drug may not shrink tumors or improve survival, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baptist Health Miami Cancer Institute
RECRUITINGMiami, Florida, 33176, United States
-
Inova Center for Personalized Health
RECRUITINGFairfax, Virginia, 22031, United States
-
UT Health San Antonio Mays Cancer Center
RECRUITINGSan Antonio, Texas, 78229, United States
-
UT MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
UW Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
-
Washington University School of Medicine
RECRUITINGBay Saint Louis, Mississippi, 63110, United States